CAS NO: | 35482-50-9 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
Cas No. | 35482-50-9 |
化学名 | 5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol |
Canonical SMILES | CC1=C[C@@H](C2=C(O)C=C(C)C=C2O)[C@H](C(C)=C)CC1 |
分子式 | C17H22O2 |
分子量 | 258.4 |
溶解度 | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | O-1821 is an cannabidiol analog with similar structure to O-1918, a selective antagonist of abnormal cannabidiol. Abnormal cannabidiol, a synthetic regioisomer of cannabidiol, fails to elicit either central cannabinoid (CB1) or peripheral cannabinoid (CB2) receptors and is lack of psychotropic activity. It can induce endothelium-dependent vasodilation through a CB1/CB2/nitric oxide-independent mechanism. In vitro: O-1821 is a cannabidiol analog with similar structure to O-1918, which was identified as a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (CB1)/peripheral cannabinoid (CB2) receptors endothelial receptor. It was found that O-1918 could not bind to CB1 or CB2 receptors and thus could not cause vasorelaxation at concentrations up to 30 μM, but it could cause concentration-dependent inhibition of the vasorelaxant effects of abn-cbd and anandamide. Moreover, in human umbilical vein endothelial cells, abn-cbd was able to induce phosphorylation of p42/44 mitogenactivated protein kinase and protein kinase B/Akt, which could be inhibited by O-1918 or by phosphatidylinositol 3 (PI3) kinase inhibitors [1]. In vivo: O-1918 was found to be able to inhibit the hypotensive effect of abn-cbd dose-dependently but not the hypotensive effect of the CB1 receptor agonist (-)-11-OH-Δ9-tetrahydrocannabinol dimethylheptyl in anesthetized mice [1]. Clinical trial: So far, no clinical study has been conducted. Reference: |